Pinometostat is under clinical development by Epizyme and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pinometostat’s likelihood of approval (LoA) and phase transition for Refractory Acute Myeloid Leukemia took place on 21 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 21 Nov 2022 increased Pinometostat’s LoA and PTSR for Relapsed Acute Myeloid Leukemia.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pinometostat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pinometostat overview

Pinometostat (EPZ-5676) is under development for the treatment of relapsed/refractory acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML), ovarian cancer and mixed lineage leukemia-rearranged leukemias (MLL-r) in pediatric and adult patients. The drug candidate is administered as intravenous infusion. It acts by targeting DOT1 like protein (DOT1L).

Epizyme overview

Epizyme is a biopharmaceutical company that discovers, develops, and markets novel epigenetic therapies for the treatment of cancer and other diseases. The company’s marketed products include Tazverik (tazemetostat), an oral, first-in-class, small-molecule inhibitor of EZH2 for the treatment of patients with metastatic or locally advanced epithelioid sarcoma and relapsed/refractory follicular lymphoma. Its pipeline products include tazemetostat for follicular lymphoma, DLBCL, epithelioid sarcoma and prostate cancer; PRMT 1 Inhibitor (GSK3368715) for solid tumors and DLBCL; and PRMT5 (GSK3368715) for solid tumors and blood cancer. The company develops products through a proprietary drug discovery platform and collaboration with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Quick View Pinometostat LOA Data

Report Segments
  • Innovator
Drug Name
  • Pinometostat
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.